BIONTECH SE ADR
Acción · US09075V1026 · BNTX · A2PSR2 (XFRA)
95,21 EUR
Precio de cierre XFRA 06.06.2025:
96,45 EUR
Frankfurt (XNAS) · Precios actuales y gráficos en MoneyPeak
06.06.2025 22:29
Cotizaciones actuales de BIONTECH SE ADR
Bolsa | Ticker | Moneda | Última operación | Precio | Variación diaria |
---|---|---|---|---|---|
![]() NASDAQ |
BNTX
|
USD
|
06.06.2025 22:29
|
108,54 USD
| 110,15 USD
-1,46 %
|
![]() Frankfurt |
22UA.F
|
EUR
|
06.06.2025 17:13
|
96,45 EUR
| 97,75 EUR
-1,33 %
|
Rendimiento
Día | Semana | Mes | 3 meses | 6 meses | 1 año | 5 años |
---|---|---|---|---|---|---|
0,00 % | 12,96 % | 13,69 % | -6,90 % | -17,32 % | 1,06 % | 118,66 % |
Perfil de la empresa para BIONTECH SE ADR Acción
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Fondos invertidos
Los siguientes fondos han invertido en: BIONTECH SE ADR invertido:
Fondo | Vol. en millones 862,43 | Porcentaje (%) 2,02 % |
Datos de la empresa
Nombre BIONTECH SE ADR
Empresa BioNTech SE
Símbolo BNTX
Sitio web
https://www.biontech.de
Mercado principal
Frankfurt

WKN A2PSR2
ISIN US09075V1026
Tipo de valor Acción
Sector Healthcare
Industria Biotechnology
CEO Dr. Ugur Sahin M.D.
Capitalización de mercado 21 Mrd.
País Alemania
Moneda EUR
Empleados 6,8 T
Dirección An der Goldgrube 12, 55131 Mainz
Fecha de OPV 2019-10-11
Símbolos de cotización
Nombre | Símbolo |
---|---|
Frankfurt | 22UA.F |
NASDAQ | BNTX |
XETRA | 22UA.DE |
Otras acciones
Los inversores que tienen BIONTECH SE ADR también tienen las siguientes acciones en su cartera:
La plataforma financiera MoneyPeak rastrea y analiza inversiones y carteras.
Desde depósitos de valores hasta compras de criptomonedas.
Útil, simple y gratuito. Acciones, ETF, ETC, ETN, índices, fondos, bonos, certificados, divisas, opciones, derechos de suscripción.
Útil, simple y gratuito. Acciones, ETF, ETC, ETN, índices, fondos, bonos, certificados, divisas, opciones, derechos de suscripción.